Zydus Lifesciences Terminates 50:50 Joint Venture With Sunshine Healthcare; Shares Trade Lower

Mumbai, November 12: Zydus Lifesciences Limited has informed stock exchanges that its proposed joint venture with Sunshine Healthcare Lanka Limited has been terminated following delays in obtaining the required regulatory approvals. The company disclosed the development in a regulatory filing dated November 12, 2026. The proposed transaction involved Zydus Sunshine Lifesciences (Private) Limited, a subsidiary of Sunshine Healthcare Lanka Limited. Under the original arrangement, Zydus Lifesciences was expected to acquire a 50% equity stake in the entity, which would subsequently operate as a 50:50 joint venture between the two companies.

Zydus Lifesciences Ends Proposed Joint Venture Following Regulatory Delays

Zydus Lifesciences had initially announced the proposed transaction on June 26, 2026, after Zydus Lifesciences Limited and Sunshine Healthcare Lanka Limited executed a Share Subscription and Shareholders’ Agreement. Under the arrangement, Zydus Lifesciences planned to subscribe to 50% of the total paid-up equity share capital of Zydus Sunshine Lifesciences (Private) Limited. Following the proposed subscription, the entity was expected to become a jointly owned company, with both partners holding equal equity stakes. The transaction was originally expected to be completed within 90 working days, subject to the fulfilment of the agreement’s terms and necessary regulatory requirements. However, the completion process extended beyond the original timeline. In an earlier communication dated October 1, 2026, the company informed stock exchanges that both parties had mutually agreed to extend the closing date, with the transaction expected to be completed by December 2026. Despite the extension, the necessary regulatory approvals remained pending. According to the latest filing, the proposed subscription and joint venture were terminated on November 11, 2026, due to delays in obtaining these approvals. The disclosure confirms that the transaction will no longer proceed under the previously announced arrangement. The company has not provided further details about any financial implications arising from the termination.

Stock Market Snapshot

Zydus Lifesciences share price traded slightly lower during the morning session on November 12, 2026. Based on the supplied intraday chart, the stock was trading at approximately ₹1,199.80 around 9:23 AM IST, compared with the previous closing reference level of approximately ₹1,199.50. The stock opened near ₹1,205 and remained around that level during the initial minutes of trading before declining towards ₹1,200. It subsequently moved below ₹1,197 around 9:16 AM IST before recovering towards ₹1,200. The chart does not provide an exact last traded price, absolute price change or percentage movement at the snapshot time. The quoted levels are approximate.

About Zydus Lifesciences

Zydus Lifesciences Limited is an Indian pharmaceutical company headquartered in Ahmedabad, Gujarat. The company operates across pharmaceutical formulations, active pharmaceutical ingredients, vaccines, biologics and other healthcare products. Zydus has a presence in domestic and international pharmaceutical markets, with operations covering research, development, manufacturing and commercialisation of healthcare products.

Conclusion

Zydus Lifesciences has formally discontinued its proposed 50:50 joint venture with Sunshine Healthcare Lanka Limited after regulatory approval delays prevented the transaction from being completed. The agreement, initially announced in June 2026, had already received a timeline extension in October before being terminated on November 11. While the company has confirmed the cancellation of the proposed investment, it has not disclosed any specific financial impact. The development brings an end to the previously announced transaction, with no further details provided regarding future arrangements between the two companies.

Source: 

• https://www.nseindia.com/get-quote/equity/ZYDUSLIFE/Zydus-Lifesciences-Limited